Effect of gender difference on platelet reactivity

Netherlands Heart Journal

Volumn 19, Issue 11, 2011, Pages 451-457

  Breet, N J ^a   Sluman, M A ^a   van Berkel, M A J P J ^a   van Werkum, J W ^a   Bouman, H J ^a   Harmsze, A M ^a   Kelder, J C ^a   Zijlstra, F ^b   Hackeng, C M ^a   ten Berg, J M ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Antiplatelet therapy; Clopidogrel Aspirin; Gender; Platelet function testing

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CLOPIDOGREL; PURINERGIC P2Y2 RECEPTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING TEST; BRAIN ISCHEMIA; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DOSE RESPONSE; FEMALE; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS;

EID: 83155177215     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-011-0189-y     Document Type: Article

References (35)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
2. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-57.
3. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med. 1998;158:981-8.
4. Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104:471-84.
5. Steinhubl SR, Berger PB, Mann III JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20.
6. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33.
7. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306-13.
8. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189-98.
9. Jochmann N, Stangl K, Garbe E, et al. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005;26:1585-95.
10. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison between platelet function tests in predicting clinical outcome in patients ndergoing coronary stent placement. JAMA. 2010;303:754-62.
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
12. Johnson M, Ramey E, Ramwell PW. Sex and age differences in human platelet aggregation. Nature. 1975;253:355-7.
13. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA. 2006;295:1420-7.
14. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-5.
15. Blais N, Pharand C, Lordkipanidze M, et al. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost. 2009;102:404-11.
16. Yee DL, Sun CW, Bergeron AL, et al. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood. 2005;106:2723-9.
17. Bailey AL, Scantlebury DC, Smyth SS. Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol. 2009;29:284-8.
18. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-34.
19. Goldschmidt PJ, Lopes N, Crwaford LE, et al. Atherothrombosis and coronary artery disease. Platelets. Elsevier/Academic Press; 2007, p. 629-96
20. Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-13.
21. Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109:166-71.
22. Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POSTSTENTING Study. J Am Coll Card. 2005;46:1820-6.
23. Sibbing D, Braun S, Morath T, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol. 2009;53:849-56.
24. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119:237-42.
25. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-33.
26. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes. 2005;54:2430-5.
27. Serebruany VL, Steinhubl SR, Berger PB, et al. Variability inplatelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246-51.
28. Stevens RF, Alexander MK. A sex difference in the platelet count. Br J Haematol. 1977;37:295-300.
29. Zuern CS, Lindemann S, Gawaz M. Platelet function and response to aspirin: gender-specific features and implications for female thrombotic risk and management. Semin Thromb Hemost. 2009;35:295-306.
30. Lordkipanidze M, Pharand C, Schampaert E, et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702-8.
31. Nielsen HL, Kristensen SD, Thygesen SS, et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry. Thromb Res. 2008;123:267-73.
32. Breet NJ, vanWerkum JW, Bouman HJ, et al. High on-aspirin platelet reactivity as measured with aggregation based, COX-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost. 2010;8:2140-8.
33. Harrison MJ, Weisblatt E. A sex difference in the effect of aspirin on "spontaneous" platelet aggregation in whole blood. Thromb Haemost. 1983;50:773-4.
34. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60.
35. Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009;54:1935-45.